Korean J Vet Res > Volume 61(1); 2021 > Article |
|
Parameter |
Type of tumor |
Number of dogs (%) | ||
---|---|---|---|---|
Epithelial (n = 12) | Mesenchymal (n = 10) | RCT (n = 9) | ||
Sex | ||||
Intact female | 2 | 1 | 0 | 3 (9.7) |
Spayed female | 8 | 5 | 5 | 18 (58.1) |
Intact male | 0 | 1 | 1 | 2 (6.5) |
Castrated male | 2 | 3 | 3 | 8 (25.8) |
Surgery | ||||
Yes | 9 | 7 | 3 | 19 (61.3) |
No | 3 | 3 | 6 | 12 (38.7) |
Margin (n = 19) | ||||
Complete* | 3 | 3 | 0 | 6 (31.6) |
Incomplete | 6 | 4 | 3 | 13 (68.4) |
Mitotic figure (n = 19) | ||||
< 10 (/10 high per field) | 7 | 4 | 2 | 13 (68.4) |
≥ 10 (/10 high per field) | 2 | 3 | 1 | 6 (31.6) |
Disease setting | ||||
Gross | 5 | 3 | 7 | 15 (48.4) |
Micro | 7 | 7 | 2 | 16 (51.6) |
Distant metastasis | ||||
Present† | 0 | 2 | 1 | 3 (9.7) |
Absent | 12 | 8 | 8 | 28 (90.3) |
Regional enlarged LN | ||||
Yes‡ | 6 | 3 | 5 | 14 (45.2) |
No | 6 | 7 | 4 | 17 (54.8) |
Chemotherapy | ||||
Sole | 9 | 8 | 4 | 21 (67.7) |
Multiple§ | 3 | 2 | 5 | 10 (32.3) |
Underlying disease | ||||
Yes | 5 | 2 | 3 | 10 (32.3) |
No | 7 | 8 | 6 | 21 (67.7) |
Variable | Number of dogs | Kaplan-Meier method (d) | |||||
---|---|---|---|---|---|---|---|
PFS* | MST | ||||||
Mean | SE | 95% CI | Median | SE | 95% CI | ||
Total | 31 | 470.8 | 51.3 | (370.3, 571.3) | 199.0 | 56.3 | (88.6, 309.4) |
Sex | |||||||
F/SF | 21 | 417.7 | 46.3 | (326.9, 508.4) | 220.0 | 69.1 | (84.5, 355.5) |
M/CM | 10 | 417.8 | 91.2 | (239.1, 596.6) | 187.0 | 34.0 | (120.4, 253.6) |
Surgery | |||||||
Yes | 19 | 439.7 | 64.1 | (314.0, 565.4) | 290.0 | 56.9 | (178.5, 401.5) |
No | 12 | 450.1 | 49.1 | (353.8, 546.4) | 154.0 | 23.0 | (109.0, 199.0) |
Type of tumor | |||||||
Mesenchymal | 10 | 315.4 | 63.6 | (190.8, 439.9) | 199.0 | 6.0 | (187.3, 210.7) |
Epithelial | 12 | 558.7 | 62.7 | (435.8, 681.7) | 311.0 | 132.8 | (50.7, 571.3) |
RCT | 9 | 420.8 | 65.6 | (292.1, 549.4) | 156.0 | 22.4 | (112.2, 199.8) |
Tx setting | |||||||
Micro | 16 | 410.0 | 69.3 | (274.2, 545.8) | 290.0 | 64.3 | (163.9, 416.1) |
Gross | 15 | 463.1 | 41.4 | (382.0, 544.2) | 169.0 | 25.7 | (118.6, 219.4) |
Tx response | |||||||
PD | 9 | - | - | - | 156.0 | 23.7 | (109.5, 202.5) |
SD | 6 | - | - | - | 187.0 | 36.1 | (116.1, 257.9) |
PR | 4 | - | - | - | 133.0 | 32.0 | (70.3, 195.7) |
CR | 3 | - | - | - | 311.0 | - | - |
NED | 9 | - | - | - | 656.0 | 0.0 | - |
Chemotherapy | |||||||
Multiple | 10 | 388.6 | 66.5 | (258.3, 518.9) | 169.0 | 45.0 | (80.8, 257.2) |
Sole | 21 | 463.2 | 63.9 | (337.9, 588.4) | 289.0 | 81.1 | (130.1, 447.9) |
Distant metastasis | |||||||
Yes | 3 | 90.3 | 39.5 | (13.0, 167.7) | 187.0 | 0.0 | - |
No | 28 | 493.0 | 52.4 | (390.2, 595.7) | 220.0 | 65.4 | (91.8, 348.2) |
Regional enlarged LN | |||||||
Yes | 14 | 224.1 | 39.0 | (147.7, 300.6) | 169.0 | 11.0 | (147.5, 190.5) |
No | 17 | 552.6 | 53.5 | (447.7, 657.6) | 289.0 | 57.9 | (175.5, 402.5) |
Underlying disease | |||||||
Yes | 10 | 424.5 | 90.1 | (247.9, 601.1) | 187.0 | 39.5 | (109.5, 264.5) |
No | 21 | 412.8 | 47.7 | (319.3, 506.4) | 289.0 | 54.9 | (181.4, 396.6) |
Toxicity | |||||||
Yes | 14 | 469.1 | 45.4 | (380.1, 558.2) | 289.0 | 73.3 | (145.4, 432.6) |
No | 17 | 388.4 | 74.6 | (242.1, 534.7) | 199.0 | 51.3 | (98.5, 299.5) |
Variable† | PFS | |||
---|---|---|---|---|
HR | 95% CI | p-value | ||
Surgery | 69.06 | (0.86, 5,560.44) | 0.06 | |
Type of tumor | ||||
Epithelial | 0.02 | (0.00, 0.68) | 0.03* | |
RCT | 0.01 | (0.00, 0.61) | 0.03* | |
Chemotherapy | 42.66 | (1.83, 991.88) | 0.02* | |
Distant metastasis | 663.52 | (2.87, 153,515.22) | 0.02* | |
Regional enlarged LN | 4.88 | (0.48, 49.67) | 0.18 | |
Duration of administration | 0.97 | (0.95, 1.00) | 0.02* | |
Toxicity | 0.11 | (0.01, 2.03) | 0.14 |
Variable† | MST | |||
---|---|---|---|---|
HR | 95% CI | p-value | ||
Surgery | 91.62 | (1.17, 7,149.10) | 0.04* | |
Type of tumor | ||||
Epithelial | 0.02 | (0.00, 0.62) | 0.03* | |
RCT | 0.30 | (0.02, 3.50) | 0.33 | |
Tx setting | 0.00 | (0.00, 0.05) | < 0.01** | |
Tx response | ||||
SD | 0.00 | (0.00, 0.05) | < 0.01** | |
PR | 0.09 | (0.00, 3.18) | 0.19 | |
CR | 0.00 | (0.00, 1.91) | 0.07 | |
NED | 0.02 | (0.00, 0.41) | 0.01* | |
Regional enlarged LN | 6.86 | (1.05, 44.87) | 0.04* | |
Duration of administration | 0.97 | (0.95, 1.00) | 0.03* | |
Underlying disease | 17.27 | (2.00, 149.06) | < 0.01** | |
Toxicity | 22.07 | (1.85, 263.21) | 0.01* |
HR, hazard ratio; CI, confidence interval; RCT, round cell tumor; Tx, treatment; SD, stable disease; PR, partial response; CR, complete response; NED, no evidence of disease; LN, lymph node; PD, progressive disease.
Variable* |
MST |
||
---|---|---|---|
HR | 95% CI | p-value | |
Mitotic count | 1.02 | (0.98, 1.07) | 0.33 |
Margin | 0.20 | (0.02, 2.26) | 0.19 |
Distant metastasis | 0.00 | (0.00, -) | 0.99 |
Regional enlarged LN | 2.01 | (0.35, 11.46) | 0.43 |
Category | Term |
Number* |
Incidence rate† | ||
---|---|---|---|---|---|
Grade 1 | Grade 2 | Grade 3 | (% in dogs with observed AEs) | ||
Constitutional | Lethargy | 1 | 2 | . | 6.3 (3.1) |
Weight loss | 1 | . | . | ||
Gastrointestinal | Inappetence | 2 | 3 | 1 | 28.6 (12.9) |
Diarrhea | 2 | 3 | . | ||
Vomiting | 2 | 2 | . | ||
Hematologic | Neutropenia | 6 | 1 | . | 20.6 (9.3) |
Lymphopenia | . | . | . | ||
Anemia | 5 | 1 | . | ||
Biochemical | Increased ALT activity | 2 | 2 | 1 | 39.7 (17.9) |
Increased ALP activity | 1 | 2 | 2 | ||
Increased BUN | 4 | . | 3 | ||
Increased Creatinine | 4 | 3 | 1 | ||
Renal | Proteinuria | 1 | . | 1 | 3.2 (1.4) |
Cardiovascular | Syncope | . | . | 1 | 3.2 (1.4) |
Hypertension | 1 | . | . | ||
Dermatologic | Alopecia | 1 | . | . | 3.2 (1.4) |
Hyperpigmentation | 1 | . | . | ||
Total (number) | 34 | 19 | 10 | ||
Total (%) | 54.0 | 30.2 | 15.8 | 100.0 (45.2) |
Seo-In Choi
https://orcid.org/0000-0003-0328-8874
Ye-Lim Nam
https://orcid.org/0000-0001-5658-1893
Jin-Kyoung Kim
https://orcid.org/0000-0002-3618-2884
Hyung-Jin Park
https://orcid.org/0000-0002-4383-1037
Kun-Ho Song
https://orcid.org/0000-0001-8478-2035
Kyoung Won Seo
https://orcid.org/0000-0002-1561-3278